Madam Therapeutics

Antimicrobial resistance

Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years. Inappropriate prescribing of antibiotics has been attributed to a number of causes, including people who insist on antibiotics, physicians who simply prescribe them as they feel they do not have time to explain why they are not necessary, and physicians who do not know when to prescribe antibiotics or else are overly cautious for medical legal reasons.

As an example, methicillin-resistant Staphylococcus aureus (MRSA) remains worldwide a major threat, and is the most important cause of antibiotic-resistant healthcare-associated infections worldwide. Infections with MRSA result in prolonged hospital stay and increased mortality rates. The proportion of invasive S. aureus isolates that are MRSA remains above 25% in more than one quarter of EU countries.

It is essential that the antibiotic research community works together to ensure that societal needs for novel and effective antibiotics remain fulfilled for the foreseeable future. Given the fact that it takes at least 10 years to deliver efficacious medicines to patients it is crucial that the research delivers new antimicrobial agents as soon as possible.


Our AMPs form such a new approach to overcome antimicrobial resistance. Our AMPs do not have to developed for scratch, and have completed most of the pre-clinical development. This will save many (costly) years of development.